

# David E Gerber

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6134159/david-e-gerber-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

216  
papers

13,068  
citations

43  
h-index

113  
g-index

247  
ext. papers

16,317  
ext. citations

6.4  
avg, IF

6.46  
L-index

#	Paper	IF	Citations
216	Reply to A. Grand et al.. <i>JCO Oncology Practice</i> , <b>2022</b> , OP2100821	2.3	
215	Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.. <i>Cancer Immunology, Immunotherapy</i> , <b>2022</b> , 1	7.4	2
214	Implementation and Uptake of Rural Lung Cancer Screening.. <i>Journal of the American College of Radiology</i> , <b>2022</b> ,	3.5	1
213	Association between immune-related adverse event timing and treatment outcomes.. <i>OncImmunity</i> , <b>2022</b> , 11, 2017162	7.2	2
212	Systemic and Intracranial Efficacy of Osimertinib in L747P-Mutant NSCLC: Case Report.. <i>JTO Clinical and Research Reports</i> , <b>2022</b> , 3, 100291	1.4	0
211	Experience, Perceptions, and Recommendations Concerning COVID-19-Related Clinical Research Adjustments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 505-512	7.3	4
210	Experience, Perceptions, and Recommendations Concerning COVID-19-Related Clinical Research Adjustments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 505-512	7.3	2
209	Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. <i>Nature Communications</i> , <b>2021</b> , 12, 7014	17.4	0
208	Upfront Brain Treatments Followed by Lung Surgery Improves Survival for Stage IV Non-small Cell Lung Cancer Patients With Brain Metastases: A Large Cohort Analysis. <i>Frontiers in Surgery</i> , <b>2021</b> , 8, 649531 <sup>3</sup>	3.3	0
207	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 723-733	2.2	94
206	Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 666691	5.3	2
205	Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9110-9110	3.2	4
204	The role of experience and clinical decision support in clinical trial accrual within oncology.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1527-1527	2.2	1
203	Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors <b>2021</b> , 9,		1
202	Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer. <i>Cancer Medicine</i> , <b>2021</b> , 10, 4752-4767	4.8	1
201	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events <b>2021</b> , 9,		58
200	Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 3351-3368	4.4	

199	Assessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e999-e1011	2.3	
198	Application of Information Technology to Clinical Trial Evaluation and Enrollment: A Review. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1559-1566	13.4	3
197	Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 156-161	8.9	6
196	Clinician Variation in Ordering and Completion of Low-Dose Computed Tomography for Lung Cancer Screening in a Safety-Net Medical System. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, e612-e620	4.9	1
195	Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials. <i>Clinical Drug Investigation</i> , <b>2021</b> , 41, 161-167	3.2	2
194	Reimbursement Matters: Overcoming Barriers to Clinical Trial Accrual. <i>Medical Care</i> , <b>2021</b> , 59, 461-466	3.1	0
193	Survival of women diagnosed with breast cancer and who have survived a previous cancer. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 187, 853-865	4.4	1
192	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2416-2423	12.9	7
191	Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers. <i>Cancer Research</i> , <b>2021</b> , 81, 3441-3443	10.1	
190	Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes. <i>JCO Oncology Practice</i> , <b>2021</b> , OP2100169	2.3	1
189	Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. <i>Cancer Biology and Therapy</i> , <b>2021</b> , 22, 455-464	4.6	1
188	Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG-ACRIN E2805 trial. <i>Cancer Medicine</i> , <b>2021</b> , 10, 5917-5924	4.8	1
187	Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1497-1505	13.4	4
186	Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. <i>Clinical Chemistry</i> , <b>2020</b> , 66, 779-793	5.5	32
185	A randomized trial of mail and email recruitment strategies for a physician survey on clinical trial accrual. <i>BMC Medical Research Methodology</i> , <b>2020</b> , 20, 123	4.7	5
184	Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?. <i>Oncologist</i> , <b>2020</b> , 25, e1242-e1245	5.7	5
183	Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud-Like Phenomenon. <i>Oncologist</i> , <b>2020</b> , 25, e753-e757	5.7	8
182	Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 326-332	4.9	2

181	Closing the gap: Contribution of surgical best practices to outcome differences between high- and low-volume centers for lung cancer resection. <i>Cancer Medicine</i> , <b>2020</b> , 9, 4137-4147	4.8	3
180	DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden. <i>Cell Reports Medicine</i> , <b>2020</b> , 1,	18	26
179	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifestuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 364-372	12.9	12
178	Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology. <i>Cancer</i> , <b>2020</b> , 126, 1605-1613	6.4	3
177	Definition and Coordination of Roles and Responsibilities Among Cancer Center Clinic and Research Personnel. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, e64-e74	2.3	1
176	Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231258	3.7	2
175	EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. <i>Nature Cancer</i> , <b>2020</b> , 1, 394-409	15.4	17
174	Thyroid dysfunction and immune checkpoint inhibitor outcomes.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e15103-e15103	2.2	1
173	Immune checkpoint inhibition-induced myocarditis in cancer patients: Proposal of a detection and management strategy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e15116-e15116	2.2	1
172	ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS9077-TPS9077	2.2	11
171	Acute hemolytic transfusion reaction secondary to anti-Fy3. <i>Immunohematology</i> , <b>2020</b> , 21, 48-52	0.4	9
170	Immunotherapy Use in Patients With Lung Cancer and Comorbidities. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2020</b> , 26, 525-536	2.2	2
169	Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage. <i>JTO Clinical and Research Reports</i> , <b>2020</b> , 1, 100094	1.4	
168	Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e21571-e21571	2.2	0
167	Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e15126-e15126	2.2	
166	Survival among colorectal cancer patients with a history of previous cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16146-e16146	2.2	
165	Preventable patient acute mortality after EMR-generated QTc alerts.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e19359-e19359	2.2	
164	Correlating immune toxicity, blood cell counts, and overall survival in cancer patients receiving immune therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3043-3043	2.2	

163	Survival among breast cancer patients with a history of previous cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e14080-e14080	2.2	
162	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. <i>Lung Cancer</i> , <b>2020</b> , 139, 60-67	5.9	48
161	Timing, Sites, and Correlates of Lung Cancer Recurrence. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 127-135.e3	4.9	4
160	Stakeholder engagement to initiate lung cancer screening in an urban safety-net health system. <i>Healthcare</i> , <b>2020</b> , 8, 100370	1.8	1
159	QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 21-27.e5	4.9	0
158	DC-HIL/Gpmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1449-1459	12.9	5
157	Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer. <i>Oncology</i> , <b>2020</b> , 98, 179-186		9
156	Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 520-526	4.9	3
155	Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?. <i>EBioMedicine</i> , <b>2020</b> , 60, 103006	8.8	
154	Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6017-6027	12.9	7
153	Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 64, 93-101	12.7	62
152	Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 515-522	5.7	4
151	Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1911519	10.4	29
150	Conceptual Model for Accrual to Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1993-1996	2.2	14
149	Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer. <i>Cancer Informatics</i> , <b>2019</b> , 18, 1176935119837547	2.4	6
148	Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?. <i>Cancers</i> , <b>2019</b> , 11,	6.6	36
147	Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis. <i>Lung</i> , <b>2019</b> , 197, 593-599	2.9	5
146	Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1529-1539	1	15

145	Patient and provider perspectives on delivery of oral cancer therapies. <i>Patient Education and Counseling</i> , <b>2019</b> , 102, 2102-2109	3.1	4
144	Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer. <i>Cancer</i> , <b>2019</b> , 125, 4252-4259	6.4	6
143	Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9027-9027	2.2	11
142	Variation in the assessment of immune-related adverse event occurrence, grade, and timing.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9047-9047	2.2	1
141	Expression of soluble DC-HIL/gpnmb receptor in the blood of metastatic non-small cell lung carcinoma treated with anti-PD1/PDL1 monoclonal antibodies.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e14038-e14038	2.2	
140	Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. <i>Head and Neck</i> , <b>2019</b> , 41, 1928-1934	4.2	12
139	Mobile Device Applications for Electronic Patient Portals in Oncology. <i>JCO Clinical Cancer Informatics</i> , <b>2019</b> , 3, 1-8	5.2	6
138	NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2601-2609	12.9	21
137	Immune dysregulation in cancer patients developing immune-related adverse events. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 63-68	8.7	64
136	Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e152-e157	4.9	14
135	Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. <i>Oncotarget</i> , <b>2018</b> , 7, e1440168	7.2	25
134	Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2018</b> , 117, 44-49	5.9	11
133	Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers. <i>Statistics in Medicine</i> , <b>2018</b> , 37, 2516-2529	2.3	4
132	Paraneoplastic Syndromes <b>2018</b> , 661-674		1
131	Characteristics of Patients Using Patient Portals in Oncology. <i>JAMA Oncology</i> , <b>2018</b> , 4, 416-418	13.4	8
130	How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. <i>Lung Cancer</i> , <b>2018</b> , 115, 97-102	5.9	14
129	Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma: A large cohort analysis. <i>Lung Cancer</i> , <b>2018</b> , 120, 22-26	5.9	5
128	Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, e173501	13.4	406

127	Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1363-1372	8.9	76
126	Statistical justification of expansion cohorts in phase 1 cancer trials. <i>Cancer</i> , <b>2018</b> , 124, 3339-3345	6.4	1
125	Development and Validation of a Nomogram Prognostic Model for SCLC Patients. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1338-1348	8.9	66
124	TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 2500-2518	15.9	48
123	Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database. <i>Oncotarget</i> , <b>2018</b> , 9, 24470-24479	3.3	10
122	Underlying host immune dysregulation in cancer patients developing immune-related adverse events.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3030-3030	2.2	
121	Use of QTc-prolonging medications among patients with lung cancer: implications for clinical trials and standard clinical care.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e20529-e20529	2.2	
120	A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21043-e21043	2.2	2
119	Mobile device access to electronic patient portals in oncology: Potential implications for patient and practice experiences.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 179-179	2.2	
118	Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical Trials. <i>Blood</i> , <b>2018</b> , 132, 2267-2267		
117	Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer: An Initial Report From the Surveillance, Epidemiology, and End Results Program. <i>JAMA Oncology</i> , <b>2018</b> , 4, 832-836	13.4	58
116	Oligometastatic Non-Small-Cell Lung Cancer: How Should We Define and Manage It?. <i>Journal of Oncology Practice</i> , <b>2018</b> , 14, 32-34	3.1	2
115	Phase 1 study of ARQ 761, a Elapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 928-936	8.7	37
114	Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 472-478	35.1	44
113	Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition. <i>Lung Cancer</i> , <b>2017</b> , 105, 14-16	5.9	12
112	Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 717-725	8.7	31
111	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology</i> , <b>2017</b> , 18, 31-41	21.7	605
110	Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 626-630	4.9	5

109	A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. <i>Oncologist</i> , <b>2017</b> , 22, 1024-e89	5.7	15
108	Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. <i>Journal of Surgical Oncology</i> , <b>2017</b> , 116, 83-88	2.8	17
107	Upper lip metastasis of sarcomatoid carcinoma of the lung - an unusual site of disease: a case report. <i>Journal of Medical Case Reports</i> , <b>2017</b> , 11, 18	1.2	3
106	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 333-339	4.9	32
105	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , <b>2017</b> , 111, 108-115	5.9	11
104	Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines. <i>Journal of Oncology Practice</i> , <b>2017</b> , 13, e982-e991	3.1	2
103	Cancer Center Clinic and Research Team Perceptions of Identity and Interactions. <i>Journal of Oncology Practice</i> , <b>2017</b> , 13, e1021-e1029	3.1	8
102	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. <i>Lung Cancer</i> , <b>2017</b> , 112, 195-199	5.9	7
101	Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1489-1495	8.9	27
100	Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1446-1450	8.9	13
99	Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial. <i>Contemporary Clinical Trials</i> , <b>2017</b> , 60, 78-85	2.3	12
98	ALK alterations and inhibition in lung cancer. <i>Seminars in Cancer Biology</i> , <b>2017</b> , 42, 81-88	12.7	20
97	Oncology Nursing Perceptions of Patient Electronic Portal Use: A Qualitative Analysis. <i>Oncology Nursing Forum</i> , <b>2017</b> , 44, 165-170	1.7	6
96	A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. <i>Translational Cancer Research</i> , <b>2017</b> , 6, S78-S82	0.3	5
95	Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 114-114	2.2	
94	Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 132-3	13.4	2
93	Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 2022-2026	8.9	60
92	Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1507-1508	13.4	80



91	Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. <i>Lung Cancer</i> , <b>2016</b> , 98, 106-113	5.9	33
90	Choroid plexus papilloma-A case highlighting the challenges of extrapolating pediatric chemotherapy regimens to adult populations. <i>Journal of Oncology Pharmacy Practice</i> , <b>2016</b> , 22, 170-4	1.7	2
89	Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 169-76	4.9	15
88	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 453-74	8.9	106
87	Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies. <i>Annals of Translational Medicine</i> , <b>2016</b> , 4, 529	3.2	10
86	Increase in Cancer Center Staff Effort Related to Electronic Patient Portal Use. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, e981-e990	3.1	17
85	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2969-79	2.2	322
84	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2980-7	2.2	338
83	Resolving Rivalries and Realigning Goals: Challenges of Clinical and Research Multiteam Systems. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 1020-1028	3.1	16
82	Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. <i>Cancer Cell</i> , <b>2016</b> , 30, 940-952	24.3	73
81	Radiation-induced KRAS G12V mutant lung adenocarcinoma in a never smoker. <i>Cancer Treatment Communications</i> , <b>2016</b> , 7, 8-10		
80	Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1357-1362	8.9	25
79	Chemotherapy for Advanced Non-small Cell Lung Cancer. <i>Cancer Treatment and Research</i> , <b>2016</b> , 170, 119-49	3.5	16
78	Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. <i>Lung Cancer</i> , <b>2015</b> , 87, 232-40	5.9	17
77	A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). <i>Lung Cancer</i> , <b>2015</b> , 89, 66-70	5.9	44
76	Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e25-6	2.2	26
75	Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	61
74	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, S1-63	8.9	102

73	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1627-39	59.2	5964
72	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 72-81	4	48
71	Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2015</b> , 90, 534-41	5.9	32
70	Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?. <i>Clinical and Translational Science</i> , <b>2015</b> , 8, 526-32	4.9	22
69	Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, Elapachone. <i>Scientific Reports</i> , <b>2015</b> , 5, 17066	4.9	40
68	Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, e86-e88	8.9	42
67	Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2015</b> , 147-62	7.1	9
66	Impact of NCI-mandated scientific review on protocol development and content. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 409-16	7.3	2
65	ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer. <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 97, 447-50	6.1	40
64	Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations. <i>Oncologist</i> , <b>2015</b> , 20, 674-82	5.7	13
63	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5439-44	12.9	76
62	Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 5, 493-503	2.2	12
61	Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2014</b> , 86, 231-6	5.9	32
60	Intramedullary spinal cord hemorrhage after treatment with bevacizumab in a long-term survivor with metastatic non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, e60-1	8.9	0
59	Management and future directions in non-small cell lung cancer with known activating mutations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , e353-65	7.1	62
58	Simultaneous acute myeloid leukemia and mesothelioma diagnoses in a long-term survivor of the 1984 Bhopal gas leak. <i>Acta Oncologica</i> , <b>2014</b> , 53, 984-8	3.2	
57	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3824-30	2.3	182
56	Stigma among patients with lung cancer: a patient-reported measurement model. <i>Psycho-Oncology</i> , <b>2014</b> , 23, 81-92	3.9	78

55	Impact of prior cancer on eligibility for lung cancer clinical trials. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	66
54	Predictors and intensity of online access to electronic medical records among patients with cancer. <i>Journal of Oncology Practice</i> , <b>2014</b> , 10, e307-12	3.1	60
53	A reevaluation of CD22 expression in human lung cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 263-71	10.1	10
52	Maintenance therapy for advanced lung cancer: who, what, and when?. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2983-90	2.2	12
51	Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2013</b> , 14, 644-50	4.9	27
50	Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2013</b> , 80, 326-32	5.9	23
49	Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2013</b> , 19, 247-62	2.2	14
48	Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1009-20	2.2	104
47	BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 992-1001	6.1	80
46	Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 1308-16	8.9	21
45	A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2507-2507	2.2	8
44	A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8072-8072	2.2	23
43	A phase II trial of second-line erlotinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8074-8074	2.2	3
42	Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8095-8095	2.2	6
41	Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8088-8088	2.2	0
40	Association between baseline tumor dimensions and survival in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8046-8046	2.2	
39	Prevalence and predictors of online patient access to electronic medical records among patients with cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 35-35	2.2	
38	"Pure and wholesome": Stephen Allen, cholera, and the nineteenth-century New York City water supply. <i>The Pharos of Alpha Omega Alpha-honor Medical Society Alpha Omega Alpha</i> , <b>2013</b> , 76, 18-27		

37	A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. <i>Lung Cancer</i> , <b>2012</b> , 77, 567-71	5.9	75
36	Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center. <i>Clinical Lung Cancer</i> , <b>2012</b> , 13, 448-57	4.9	30
35	Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer. <i>Patient Education and Counseling</i> , <b>2012</b> , 89, 102-8	3.1	21
34	Stromal platelet-derived growth factor receptor $\alpha$ (PDGFR $\alpha$ ) provides a therapeutic target independent of tumor cell PDGFR $\alpha$ expression in lung cancer xenografts. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 2473-82	6.1	31
33	Consent timing and experience: modifiable factors that may influence interest in clinical research. <i>Journal of Oncology Practice</i> , <b>2012</b> , 8, 91-6	3.1	15
32	Targeting the PI3K pathway for cancer therapy. <i>Future Medicinal Chemistry</i> , <b>2012</b> , 4, 1153-69	4.1	43
31	Miscellaneous agents--cytotoxics and hormonal agents. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, S387-9	8.9	
30	How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experience. <i>PLoS ONE</i> , <b>2012</b> , 7, e52313	3.7	7
29	Stromal and antitumor effects of BIBF 1120 (nintedanib) in a preclinical lung cancer model. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e13563-e13563	2.2	
28	The impact of renal function on therapeutic options for advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e18076-e18076	2.2	
27	Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 365-71	8.9	39
26	Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6888-96	12.9	58
25	Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. <i>Immunotherapy</i> , <b>2011</b> , 3, 933-44	3.8	44
24	A novel polymer gel for the delivery of local therapies to intracranial tumors: In vivo safety evaluation. <i>Journal of Biomedical Materials Research - Part A</i> , <b>2011</b> , 99, 479-84	5.4	5
23	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3307-15	2.2	343
22	Targeted therapies for lung cancer: clinical experience and novel agents. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2011</b> , 17, 512-27	2.2	80
21	Paraneoplastic syndromes: an approach to diagnosis and treatment. <i>Mayo Clinic Proceedings</i> , <b>2010</b> , 85, 838-54	6.4	379
20	Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1529-35	8.9	43

19	Cetuximab in combination therapy: from bench to clinic. <i>Cancer and Metastasis Reviews</i> , <b>2010</b> , 29, 171-80	9.6	25
18	ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. <i>Cancer Cell</i> , <b>2010</b> , 18, 548-51	24.3	188
17	Lung cancer diagnostic and treatment intervals in the United States: a health care disparity?. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 1322-30	8.9	68
16	The impact of consentor characteristics and experience on patient interest in clinical research. <i>Oncologist</i> , <b>2009</b> , 14, 468-75	5.7	17
15	Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies <b>2009</b> , 321-363		
14	The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. <i>Blood</i> , <b>2008</b> , 112, 504-10	2.2	102
13	EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. <i>Drug Development Research</i> , <b>2008</b> , 69, 359-372	5.1	34
12	Targeted therapies: a new generation of cancer treatments. <i>American Family Physician</i> , <b>2008</b> , 77, 311-9	1.3	228
11	Recent advances in radiation therapy. <i>American Family Physician</i> , <b>2008</b> , 78, 1254-62	1.3	13
10	Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis. <i>Cancer</i> , <b>2007</b> , 109, 300-5	6.4	25
9	Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2007</b> , 59, 817-23	3.5	10
8	The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. <i>Neuro-Oncology</i> , <b>2007</b> , 9, 47-52	1	78
7	Intracranial hemorrhage during GliaSite RTS manipulation in an anticoagulated patient. <i>Journal of Radiotherapy in Practice</i> , <b>2007</b> , 6, 53-57	0.4	1
6	Emerging monoclonal antibody therapies for malignant gliomas. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 477-94	5.9	12
5	Venous Thromboembolism among 1,570 Patients Undergoing Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment and Outcomes.. <i>Blood</i> , <b>2007</b> , 110, 1628-1628	2.2	1
4	Does decompressive surgery improve outcome in patients with metastatic epidural spinal-cord compression?. <i>Nature Clinical Practice Neurology</i> , <b>2006</b> , 2, 10-1		1
3	Management of venous thromboembolism in patients with primary and metastatic brain tumors. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 1310-8	2.2	125
2	Patient education role of a pharmacist on a transplant service. <i>American Journal of Health-System Pharmacy</i> , <b>2000</b> , 57, 767-8	2.2	9

1 Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

2